Cargando…

Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients

In this monocentric prospective study, the influence on long‐term outcomes of peripheral blood levels of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) was investigated in 56 patients with acute leukemia (myeloid n = 47; lymphoid n = 9) before and after (Days+60/+90) allogeneic hematopoietic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterlin, Pierre, Béné, Marie C., Jullien, Maxime, Guillaume, Thierry, Bourgeois, Amandine Le, Garnier, Alice, Debord, Camille, Eveillard, Marion, Chevallier, Patrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Stem Cell Transplantation & Cellular Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660606/ https://www.ncbi.nlm.nih.gov/pubmed/38024608 http://dx.doi.org/10.1002/jha2.795

Ejemplares similares

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients
por: Peterlin, Pierre, et al.
Publicado: (2022)

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation
por: Garnier, Alice, et al.
Publicado: (2022)

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
por: Clemenceau, Beatrice, et al.
Publicado: (2022)

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Post‐transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced‐intensity conditioning allotransplant
por: Bourgeois, Amandine Le, et al.
Publicado: (2023)

Global longitudinal strain is superior to ejection fraction for long‐term follow‐up after allogeneic hematopoietic stem cell transplantation
por: Watanabe, Marika, et al.
Publicado: (2022)

Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage‐specific chimerism analysis
por: Lindahl, Hannes, et al.
Publicado: (2022)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
por: Garnier, Alice, et al.
Publicado: (2022)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Prognostic plasma biomarkers of early complications and graft‐versus‐host disease in patients undergoing allogeneic hematopoietic stem cell transplantation
por: Balakrishnan, Balaji, et al.
Publicado: (2020)

Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial
por: Peterlin, Pierre, et al.
Publicado: (2023)

Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma
por: Ligero, Marta, et al.
Publicado: (2023)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
por: Miyata, Masahiro, et al.
Publicado: (2023)

The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia
por: Kim, Dennis D. H., et al.
Publicado: (2022)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft
por: Jullien, Maxime, et al.
Publicado: (2020)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

P534: FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.
por: Peterlin, Pierre, et al.
Publicado: (2023)

Interest of the preventive and curative use of defibrotide on the occurrence and severity of sinusoidal obstruction syndrome after hematopoietic stem cell transplant in children
por: Rudebeck, Carl J., et al.
Publicado: (2022)

Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia
por: Ichikawa, Hiroya, et al.
Publicado: (2023)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2022)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Prognostic Value of Hematogones in Patients With Hematopoietic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
por: Mori, Hirotaka, et al.
Publicado: (2023)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84okhc6p7imjlqu76ejngb76rk